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Background: Home-based care in oncology is mainly reserved for patients at the end of life. Regulations regarding
home delivery of cytotoxics differ across Europe, with a notable lack of practice guidelines in most countries. This
has led to a lack of data addressing the feasibility of home-based administration of cytotoxic chemotherapy. In
advanced non-squamous non-small cell lung cancer, pemetrexed is approved as maintenance therapy after first-line
chemotherapy. In this setting, patients have the potential to be treated long-term with maintenance therapy,
which, in the absence of unacceptable toxicity, is continued until disease progression. The favourable safety profile
of pemetrexed and the ease of its administration by 10-minute intravenous infusion every 3 weeks make this drug
a suitable candidate for administration in a home setting.
Methods: Literature and regulations relevant to the home-based delivery of cytotoxic therapy were reviewed, and
a phase II feasibility study of home administration of pemetrexed maintenance therapy was designed. At least 50
patients with advanced non-squamous non-small cell lung cancer, Eastern Cooperative Oncology Group
performance status 0–1 and no progressive disease after four cycles of platinum-based first-line therapy are
required to allow investigation of the feasibility of home-based administration of pemetrexed maintenance therapy
(500 mg/m2 every 3 weeks until progressive disease or unacceptable toxicity). Feasibility is being assessed as
adherence to the home-based administration process (primary endpoint), patient safety, impact on patients’ quality
of life, patient and physician satisfaction with home care, and healthcare resource use and costs. Enrolment of
patients from the UK and Sweden, where home-based care is relatively well developed, commenced in December
2011.
Discussion: This feasibility study addresses an important aspect of maintenance therapy, that is, patient comfort
during protracted home-based chemotherapy. The study design requires unusual methodology and specific
logistics to address outcomes relevant to the home-delivery approach. This article presents a study design that
offers a novel and reproducible model for home-based chemotherapy, and provides an up-to-date overview of the
literature regarding this type of treatment.
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Lung cancer is the most common cause of cancer-
related death in Europe [1]. Non-small cell lung cancer
(NSCLC) accounts for 80–85% of all lung cancer cases,
and the majority of patients present with advanced dis-
ease [2].
Current guidelines for the treatment of patients with ad-
vanced NSCLC recommend platinum-based combination
regimens using a third-generation agent as first-line
treatment [3-5]. For patients who have not progressed at
completion of first-line treatment and have good perfor-
mance status (PS; 0–1), maintenance therapy is now
recommended [3,4,6]. The aim of maintenance therapy is
to delay disease progression and improve patient survival
while preserving health-related quality of life (HRQoL) [7].
Because maintenance therapy is, by definition, long-
term (as it relates to treatment until progression),
optimising the experience of patients during therapy is
important. In many countries, there has been an increas-
ing trend of moving healthcare services, including those
for cancer, into the community and into ambulatory or
home-based care. Such moves aim to improve the choice
and experience of patients, and make more effective and
efficient use of resources [8]. In general, home-based
treatment is associated with good patient satisfaction,
acceptability and safety, and improved HRQoL [9-14].
Home-based administration could also increase access
to treatment, reduce the need for patients to travel to
hospital and wait for treatment, and increase time spent
at home, all of which are important to patients and their
families [9]. However, some down sides to home-based
chemotherapy have been reported; for example, a lack of
support from others in a similar position and feeling less
secure at home [9,13]. In addition, it is possible that
such an approach to therapy could increase the burden
on relatives.
Home-based care in oncology is mainly reserved for
patients at the end of life. Regulations regarding home
administration of cytotoxics differ widely across Europe,
with a notable lack of practice guidelines in most coun-
tries. This has led to an important lack of data regarding
the feasibility of home-based administration of cytotoxic
chemotherapy in patients with NSCLC. We identified
one study in literature searches that considered home
administration of cytotoxic chemotherapy in this patient
population; this was a feasibility study that investigated
the home-based use of gemcitabine monotherapy as first-
line treatment in 24 patients with advanced NSCLC [9].
Patients and caregivers in this study reported positively on
home-based administration and preferred it to hospital-
based administration, with only one patient requiring a
change from home- to hospital-based administration
(because of feelings of anxiety and fainting after the
second injection of the second cycle).Pemetrexed, a multi-targeted antifolate that inhibits sev-
eral enzymes of the folate pathway, is approved as a first-
line (in combination with cisplatin) [15] and second-line
(as a single agent) treatment of advanced non-squamous
NSCLC [16]. Pemetrexed is also indicated as maintenance
therapy for patients with advanced non-squamous NSCLC
whose disease has not progressed after four cycles of
platinum-based doublet induction chemotherapy and who
have a good PS (Eastern Cooperative Oncology Group
[ECOG] PS 0–1). This approval was based on the results
of two phase III, randomised, double-blind, placebo-
controlled trials showing that single-agent pemetrexed
(with best supportive care) maintenance therapy improved
progression-free survival and overall survival (OS) [17,18]
in this patient group. Patients who enrolled in these stud-
ies received long-term pemetrexed treatment (up to 55
cycles): in the study by Ciuleanu et al. [17], patients re-
ceived a median of 5 cycles, with 48% (n = 213) and 23%
of patients (n = 103) completing >6 cycles and ≥10 cycles
of therapy, respectively, whereas in the PARAMOUNT
study [18], patients received a median of four cycles,
with 37% of patients (n = 133) and 28% (n = 99) comple-
ting >6 cycles and ≥10 cycles of therapy, respectively.
The efficacy of pemetrexed as maintenance therapy
and its favourable and well-characterised safety profile,
together with the ease of its administration by 10-
minute intravenous (i.v.) infusion every 3 weeks, make
this drug a suitable candidate for administration in an
outpatient, home-based setting. Therefore, we initiated a
study to investigate the feasibility of home-based admin-
istration of pemetrexed as maintenance therapy in pa-
tients with advanced non-squamous NSCLC. This article
describes the study design and methodology, and dis-
cusses the practicalities of providing home-based admin-
istration of maintenance chemotherapy with pemetrexed
to patients with advanced non-squamous NSCLC.
Methods
Study design and objectives
This is a multicentre, two-country, single-arm, open-
label, phase II study, designed to evaluate the feasibility
of administering pemetrexed as maintenance therapy in
a home setting to patients with stage IIIB or IV non-
squamous NSCLC.
The primary objective of this study is to assess the ad-
herence rate to pemetrexed maintenance therapy admin-
istered in a home setting. Patients will be considered
adherent unless they revert to infusions at hospital or
discontinue from the study because of the home setting.
Secondary objectives of the study include the assessment
of resource utilisation, distances travelled, the number
and length of visits, and unplanned use of healthcare re-
sources (primary or emergency care, hospitalisations).
Additional secondary objectives include the safety of
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characterisation of the types and incidences of drug
toxicities; patient HRQoL; patient and physician
satisfaction with home care; time-to-treatment failure
(TTF); and OS.
The study involves qualified investigative thoracic on-
cology sites in the UK and Sweden. The sponsor, Eli
Lilly, is responsible for overall study management, regu-
latory affairs, statistical analysis and data quality assur-
ance. The Medical Research Network, an international
clinical trial support organisation based in the UK, is
providing all support services for the home administra-
tion of chemotherapy in this study. All the nurses re-
sponsible for home-based chemotherapy administration
and care of the enrolled patients are registered nurses
who are trained and experienced in administering com-
plex therapies, standard patient assessments and proce-
dures, and recording clinical trial data into source
documents or case report forms. The study design is
illustrated in Figure 1.
The study protocol has been approved by the ethics
review board of each participating institution (investiga-
tive site). The study is being conducted in accordance
with the ethical principles of the Declaration of Helsinki
and Council for International Organizations of Medical
Sciences International Ethical Guidelines, the Inter-
national Conference on Harmonisation Good Clinical
Practice Guideline and all applicable laws and regula-
tions. All patients are required to provide a signed in-
formed consent.Figure 1 Study design.Study population
Patients with advanced (stage IIIB or IV) non-squamous
NSCLC that has not progressed radiologically or clinic-
ally after four induction cycles of platinum-based doub-
let therapy (regimen at the discretion of the physician)
and who have an ECOG PS of 0 or 1 [19] are eligible for
enrolment in this study (Table 1). Tumour responses are
assessed objectively using Response Evaluation Criteria
in Solid Tumors (RECIST; version 1.1) [20]. Sample size
calculations indicated that a minimum of 50 patients is
required for this study.Study treatment definition and schedule
Patients must start on-study treatment no earlier than
21 days and no later than 42 days from Cycle 4 Day 1 of
induction therapy. Patients receive maintenance therapy
with i.v. pemetrexed 500 mg/m2, administered over
10 minutes, on Day 1 of a 21-day cycle until progressive
disease (PD) or unacceptable toxicity, or until the patient
discontinues from the study for any other reason.
Pemetrexed is given at the full starting dose to all pa-
tients, irrespective of the previous drug regimen or dose
given during the induction phase (Figure 1).
For the purpose of this study, study treatment is de-
fined as pemetrexed maintenance therapy received at
the hospital (Cycle 1) and, thereafter, any doses received
in a home setting. All patients receive folic acid and vita-
min B12 supplementation, and prophylactic dexametha-
sone according to the pemetrexed label.
Table 1 Study inclusion and exclusion criteria
Inclusion
criteria
Willing to comply with home delivery administration
and have family or close environment support willing
to comply with home delivery administration
Histological or cytological diagnosis of non-squamous
NSCLC
Stage IIIB (not amenable to curative treatment) or IV
NSCLC prior to induction therapy [21]
Completed and not progressed after four induction
cycles of platinum-based doublet therapy (type at the
discretion of the physician). Documented radiographic
evidence of a tumour response must occur at the end
of Cycle 4 of induction therapy within 3 weeks before
receiving the first cycle of study drug (RECIST version
1.1) [20]
Received on-study treatment no earlier than 21 days
and no later than 42 days from Cycle 4 Day 1 of
induction therapy
ECOG performance status 0 or 1 [19]
Prior radiation therapy is allowed if to <25% of the
bone marrow (but not whole pelvis radiation) and the
patient has recovered from all toxicities (except for
alopecia) before enrolment
Adequate organ function (bone marrow reserve,
hepatic, renal)
Aged ≥18 years at time of screening
Females must be surgically sterile, postmenopausal or
must have a negative serum or urine pregnancy test
within 7 days prior to the first dose of study drug
Males and females with reproductive potential must
agree to use a reliable method of birth control during
the study and for 6 months following the last dose of
study drug
Estimated life expectancy ≥12 weeks





Current or prior (within last 30 days) participation in a
clinical trial involving an investigational product or non-
approved use of a drug or device
Serious concomitant systemic disorder that according
to the investigator, would compromise ability to adhere
to the protocol
Serious cardiac condition, such as myocardial
infarction within 6 months, angina or heart disease
(NYHA class III/IV)
Central nervous system malignancy or metastases
(screening not required) unless patient is asymptomatic
and radiographically stable after local therapy and
has been off corticosteroids and/or anticonvulsants
for ≥1 week
Concurrent administration of any other anti-tumour
therapy
Second primary malignancy that may affect
interpretation of results
Inability to interrupt aspirin or other non-steroidal anti-
inflammatory agents, other than aspirin ≤1.3 g/day, for
a 5-day period (8-day period for long-acting agents)
Table 1 Study inclusion and exclusion criteria (Continued)
Inability or unwillingness to take folic acid or vitamin
B12 supplementation, or corticosteroids
Pregnant or lactating
Recent (within 30 days) or concurrent yellow
fever vaccination
NSCLC = non-small cell lung cancer; RECIST = Response Evaluation Criteria in
Solid Tumors; ECOG = Eastern Cooperative Oncology Group; NYHA = New York
Heart Association Class.
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study
Patients are discontinued from the study if they revert to
hospital administration of pemetrexed maintenance
therapy or when it is decided that home-based adminis-
tration of pemetrexed should be stopped. Reasons for
discontinuation because of the home setting include pa-
tient or family decision (e.g. anxiety or dissatisfaction
with the home delivery service), physician decision (e.g.
complications related to drug administration, such as
difficult vein access), or patient non-compliance with
study home administration procedures. Hospitalisations
for serious adverse events (SAEs) are not considered a
reversion to hospital therapy when the patient returns
home to continue chemotherapy after the SAE has re-
solved. In such a situation, the next infusion can be de-
layed up to 42 days from the beginning of the previous
cycle to allow the patient to recover from the SAE and
continue pemetrexed maintenance therapy administra-
tion at home.
Reasons for patient discontinuation other than because
of the home setting include the occurrence of clinical or
objective PD; unacceptable toxicity; and investigator/
physician or sponsor discretion for reasons other than
those relating to the home setting.
Study and home administration procedures
Physical examination, weight (using the patient’s bath-
room scale for all cycles administered in the home), vital
signs, ECOG PS evaluation, serum chemistry and
haematology laboratory tests, a record of all concomitant
medications and completed HRQoL questionnaires are
obtained during the baseline period, before the first dose
of maintenance therapy, at each cycle during the study
treatment period and at the 30-day post-discontinuation
follow-up. Tumour assessments and adverse events
(AEs) data are collected during treatment and the long-
term follow-up period. Baseline procedures and adminis-
tration of the first cycle of pemetrexed occur at the
hospital (the investigative site). After the first infusion
(Cycle 1), the investigative site completes a subject refer-
ral form referring the patient to home care, confirming
that the patient had consented to the referral (informed
consent occurred during the baseline period before any
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mation required by the home care team for the appro-
priate scheduling of the home visits. An appropriately
trained nurse is then appointed to visit the patient.
The first home visit is conducted on Cycle 1, Day 19
of maintenance therapy (±2 days) to collect blood sam-
ples prior to administration of pemetrexed for Cycle 2.
At this visit, the home care nurse also collects informa-
tion on AEs, concomitant medications, ECOG PS,
weight and physical examinations (including vital signs,
blood pressure and pulse), as well as providing HRQoL
questionnaires (the EuroQol 5-Dimensional Scale [EQ-
5D] [22] and the Lung Cancer Symptom Scale [LCSS]
[23]) to be completed by the patient for the next cycle.
Blood samples are delivered to the site’s local laboratory
by the home care nurse or shipped by courier, if long
distance. The investigator prescribes the dose for the
next cycle according to the laboratory data and patient
safety monitoring.
Home care nurses are trained to manage and describe
any AE that may occur at home, including acute reac-
tions, and provide information to the primary investiga-
tor who is responsible for using that information to
determine the severity and causality of AEs, prescribe
concomitant medication to treat the AE and to adjust
pemetrexed doses when required. AE severity is assessed
using the National Cancer Institute Common Termin-
ology Criteria for Adverse Events (CTCAE), version 4.0
[24]. In addition, the home care nurse immediately
telephones the investigative site to report any SAE
(according to usual procedures) and refers the patient to
the site if required. During treatment, the primary con-
tact for the patient is always the investigator.
Tumour assessment is performed at baseline. Then, at
any time during study treatment, the investigator can
schedule radiological tests for tumour assessment,
according to local practice at the site, and evaluate these
tests to determine whether the patient should continue
receiving study treatment.
Resource utilisation questions are answered by pa-
tients/caregivers after the first infusion is adminis-
tered at the hospital (first cycle) and by patients/
caregivers and home care nurses at home (all home-
based administrations) at specified times within each
cycle, as outlined in the data collection form (Table 2).
Patient satisfaction with home care is assessed, for
those patients who receive at least four maintenance
cycles, on the day of infusion of Cycle 4 and, for all
patients, at the 30-day post-discontinuation visit
(Table 3). In addition, at the end of home treatment,
physicians will be asked to evaluate overall satisfac-
tion with home care by answering the question, ‘How
would you rate your overall satisfaction with the dis-
tant management of the patient during chemotherapyat home (very dissatisfied, somewhat dissatisfied, nei-
ther satisfied nor dissatisfied, somewhat satisfied, very
satisfied)?’.
Preparation, delivery and home administration of
pemetrexed
Pemetrexed is reconstituted according to labelling in-
structions by the site pharmacy and then either collected
by the home care nurse or, if long distance, shipped via
specialist courier to the patient on the day of treatment.
The infusion bag, properly labelled, is transported in a
rigid, refrigerated box; every nurse has a spillage kit in
his or her car in case of accident. Transportation to, and
then administration of pemetrexed at, the patient’s home
must occur within 24 hours of reconstitution. The home
care nurse administers pemetrexed using a pump to en-
sure that the drug is infused over 10 minutes. Once
pemetrexed administration is completed, the infusion
bags are collected and transported in cytotoxic sharps
bins by the home care nurses to their base, where they
are destroyed according to local regulations (e.g. under
Control of Substances Hazardous to Health regulations).
Study outcomes assessment
Home administration adherence
The duration of adherence will be calculated as the time
from the first dose at Cycle 1 (hospital administration)
until either the last day of the cycle when the decision is
made for the patient to revert to pemetrexed hospital
administration or the last day of the cycle when the pa-
tient discontinues study treatment or the study for any
of the reasons related to the home setting specified earl-
ier. From that time, patients who have met these discon-
tinuation criteria will be considered as non-adherent for
the study’s primary objective. Reasons for non-adherence
will be noted.
Efficacy
TTF is defined as the time from Day 1 of Cycle 1 to the
date of the first of the following events: discontinuation
of pemetrexed due to toxicity, PD or death due to any
cause. The duration of OS is defined as the time from
Day 1 of Cycle 1 to the date of death from any cause.
Safety and treatment exposure
Patient safety, recorded by maximum CTCAE [24] se-
verity grade and seriousness, as well as hospitalisations
and transfusions, will be assessed throughout the entire
study treatment duration and at the 30-day post-
discontinuation period for all patients who receive at
least one dose of study drug. Overall exposure to study
drug and any treatment adjustments will be recorded for
the entire treatment period.
Table 2 Resource utilisation questions, to be answered by patients/caregivers and the home care nurse*
Questions Answers
A) Questions for the patient to be answered after the first infusion (administered at the hospital).
1. How long did the whole process take, from the time you arrived to the hospital until the time you left the
hospital?
Hours: Minutes:
2a. How long did the whole process take, from the time you left home until the time you got back home again? Hours: Minutes:
2b. How far did you have to travel from home to the hospital? Miles/km (depending on
country):
2c. If you are travelling by public transport, how much does the return trip to hospital cost you? Pounds/Swedish crowns
(kronor):
B) Questions for the patient to be answered before receiving the infusion at home at each cycle.
The home care nurse can help the patient to answer these questions.
1. After your last chemotherapy, did you have any unplanned visits to the Accident and Emergency (A&E)
department?
Yes/No/Unknown
If yes, how many? 1 2 3 4 ≥5
2. After your last chemotherapy, did you require any unplanned visits to your specialist
(oncologist, pulmonologist, etc.)?
Yes/No/Unknown
If yes, how many? 1 2 3 4 ≥5
3. After your last chemotherapy, did you require any unplanned visits to your general practitioner (GP)
or family doctor?
Yes/No/Unknown
If yes, how many? 1 2 3 4 ≥5
4. After your last chemotherapy, did you require any unplanned diagnostic procedures? Yes/No/Unknown






C) Questions for the patient to be answered after receiving the infusion at home at each cycle
1. How long did the whole process take, from the time the nurse arrived until the time the nurse left your home? Hours: Minutes:
D) Questions for the caregiver to be answered after the infusion at the hospital
1. How much additional time have you taken off work or for other duties related to infusion at the hospital? Days: Hours: Minutes:
E) Questions for the caregiver to be answered after the infusion at home at each cycle
1. How much additional time have you taken off work or for other duties related to infusion at home? Days: Hours: Minutes:
F) Questions for the home care nurse
1. To be answered after the infusion at home at each cycle
a. How long did the whole process take, from the time you left the hospital to the time you got to the patient’s
home?
Hours: Minutes:
b. How long did the whole process take, from the time you arrived at the patient’s home until the time you left
patient’s home?
Hours: Minutes:
2. To be answered only during the first infusion administered at home.
How far did you have to travel from hospital to the patient’s home? Miles/km:
*These questions were developed specifically for the study.
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During the baseline period, on Day 1 of each cycle and
at the 30-day post-discontinuation visit, patient-reported
general HRQoL will be measured using the EQ-5D [22];
disease-related symptoms will be measured at the same
time-points using the LCSS (both patient and observer
scales) [23].Patient and physician satisfaction
Patient satisfaction with home care, as well as physician/in-
vestigator satisfaction with distant management of the pa-
tient, will be documented using questions composed for the
purpose of this study, at the 30-day post-discontinuation
visit and on the day of infusion for Cycle 4, for those pa-
tients who receive at least four maintenance cycles.
Table 3 Patient satisfaction with home care*
Patients should answer each question in Sections A, B, C, and D
(questions 1 to 16) on the day of infusion of Cycle 4 after home
administration of study treatment (only patients who have not
discontinued from study treatment by Cycle 4) and at the 30-day
post-discontinuation visit (all subjects).
A) Please evaluate your hospital
experience in this trial
1. What do you consider advantages of
having chemotherapy at hospital?Please
specify which ones (choose all that apply):
Support from other
patients




Safer in case something
goes wrong
Other (specify):
2. What do you consider disadvantages of
having chemotherapy at hospital?
Need to travel
Having to wait for
treatmentPlease specify which ones
(choose all that apply):
Not having a
personalised treatment
Lack of privacy on the
ward
Other (specify):
3. How would you rate your overall








4. How would you rate your overall
satisfaction with the nursing staff during







B) Please evaluate your home experience
in this trial
5. What do you do consider advantages of
having chemotherapy at home?
No need to travel
Not having to wait for
treatmentPlease specify which ones




6. What do you consider disadvantages of
having chemotherapy at home?
Lack of other patients’
support
Please specify which ones
(choose all that apply):
Extra burden for family/
friends
Safety concerns
Need to rely on one
medical specialist
Other (specify):
Table 3 Patient satisfaction with home care* (Continued)
7. How would you rate your overall







C) Could you please provide us additional
information regarding your home care
nurse during your home treatment?
8. Was the nurse an easy person to talk to? Yes/No
9. When the nurse came, did you feel he/she
had enough time to do the required
things?
Yes/No
10. Do you think the nurse had time to
discuss things with you?
Yes/No
11. Did you feel that the nurse knew enough
about you and your illness?
Yes/No
12. Were you able to get all the information
you wanted about your illness or
treatment?
Yes/No/Uncertain






14. How would you rate your overall








D) Could you please evaluate your
preferences regarding home and/or
hospital treatment?
15. Do you prefer having your chemotherapy




16. Would you recommend having
chemotherapy at home to someone else
in your same situation?
Yes/No/Not sure
*These questions were developed specifically for the study.
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The use of healthcare resources (primary care, emer-
gency facilities, hospitalisations, and unplanned diagnos-
tic tests), the number and length of visits, and distances
travelled to provide/receive the study treatment will be
documented by clinical staff and patients/caregivers, and
then collated. As the prices of resources used during
the study vary between countries, country-specific costs
obtained from external sources will be applied to the re-
sources utilised.
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The primary outcome measure is adherence to treatment
administration at home, and the range of the 95% confi-
dence interval (CI) around this estimate was used as the
basis for the sample size calculation. Kaplan–Meier
survival analysis methodology will be used to estimate the
adherence rate as this will account for those patients who
are censored (i.e. who die or discontinue treatment
and exit the study without prior reversion to hospital
administration).
As no information regarding adherence using our def-
inition was available, sample size calculation was based
on several data sources. A study using gemcitabine
home maintenance therapy found that 1 of 24 patients
reverted to hospital infusion [9]; however, to be conser-
vative, we have assumed higher rates for non-adherence.
The provisional rates for censoring were taken from the
pivotal study of pemetrexed maintenance therapy [17].
Under pre-specified assumptions, and based on Green-
wood’s formula for standard error of survival [25], with a
sample of 50 patients in the study, the rate of adherence
will be 86% by the beginning of the sixth cycle when
more than 50% of patients will be expected to discon-
tinue pemetrexed treatment.
For the primary endpoint, the rates of adherence to
home administration will be calculated for each cycle
and will be reported with their corresponding 95% CIs.
OS and TTF will be estimated using Kaplan–Meier
methodology and reported with corresponding 95% CIs.
Patient satisfaction and physician/investigator satisfac-
tion will be summarised.
Resource utilisation and HRQoL data will be summa-
rised separately for infusions received at the hospital and
at home.
Discussion
This study aims to answer a number of questions re-
garding the home-based administration of pemetrexed
maintenance therapy and the experience of patients with
advanced non-squamous NSCLC. The primary objective
is to assess whether home administration of cytotoxic
chemotherapy (pemetrexed) is feasible for patients and
healthcare personnel, as measured by the adherence rate.
Between December 1, 2011 and October 29, 2012, we
enrolled 52 patients at nine sites (two in Sweden and
seven in the UK).
The Department of Health Cancer Reform Strategy in
the UK indicates that care should be delivered in the
appropriate setting and that “there are significant oppor-
tunities to shift some services from inpatient to ambula-
tory care… this shift improves patient experience and
outcomes and increases the efficiency of services” [8]. In
addition, home care may offer benefits to the patient
and caregivers, personally, psychologically and socially.In the UK, home chemotherapy is delivered by a few
National Health Service (NHS) trusts and by several pri-
vate healthcare companies to a limited number of pa-
tients meeting criteria specific to each organisation [26],
and has not been well studied or utilised in that country.
However, the recent report ‘Chemotherapy Services in
the Community – A Guide for PCTs’ cites evidence from
countries such as France and the USA, where home
chemotherapy is more frequently used, and Australia
and Spain, where home administration of chemotherapy
has been studied. The evidence demonstrates that
home-based chemotherapy is generally preferred by pa-
tients and carers, and has similar or slightly higher costs
than hospital-delivered chemotherapy [26].
Our study is being conducted in the UK and Sweden
because these European countries allow chemotherapy
to be delivered to patients at home by qualified nurses
trained in such procedures. UK NHS trusts that are
offering home-based administration of chemotherapy
provide institutional guidelines for the management of
cytotoxic agents that are in general agreement with the
protocol of our study. In Sweden, chemotherapy is usu-
ally administered only at highly specialised centres; how-
ever, these hospitals often service wide geographic areas
(in some instances, the distance from the most rural
areas to the hospital can be more than 130 km). There-
fore, most counties in Sweden have well-developed
systems for delivering home care to patients, although
administration of chemotherapy is unusual and is con-
trolled by the Swedish Work Environment Authority
statute AFS 2005:5.
However, regulations concerning the home administra-
tion of chemotherapy differ across Europe, and in a
number of countries (e.g. Germany, Italy and Spain),
regulatory authorities have provided no specific guide-
lines regarding home administration of cytotoxic chemo-
therapy, although some guidance is available. In Italy,
home administration of i.v. cytotoxic drugs is not
allowed, except in exceptional cases, such as when it is
physically impossible for the patient to come to the hos-
pital; in these instances, only a physician can administer
home treatment. Similarly, home administration of i.v.
cytotoxic drugs is not allowed in Spain or in Germany
where the high density of hospitals and oncological/
pneumological specialist offices seems to obviate the
need for such a treatment strategy. In addition, the i.v.
administration of chemotherapeutics is the responsibility
of physicians in Germany and cannot be delegated.
In contrast, home administration of selected cytotoxic
chemotherapy is allowed and encouraged in France [27],
although it appears to be underutilised [28,29], and this
country has well-defined official guidelines for such pro-
cedures that are in general agreement with the protocols
used in our study. In France, in common with guidelines
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and trained in the handling, administration and manage-
ment of cytotoxic drugs, to administer these agents in
the home setting. However, in France, the organisation
of home care must be co-ordinated and supervised by a
physician (with a mandatory patient pre-treatment visit
by a physician), and should actively involve the referent
general practitioner, who must accept this responsibility
[30]. In addition, patients are carefully selected for
eligibility, and a protocol of emergency procedures needs
to be established and validated by all those involved in
the provision of home administration of i.v. cytotoxic
chemotherapy, including the patient and caregiver(s).
Although the first infusion is required at hospital, some
agents are not considered suitable for home administra-
tion in France; only cytotoxic agents with easy and safe
administration procedures are eligible, and central ven-
ous access using a Port-A-Cath device is mandatory for
all i.v. drugs administered at home. Agents requiring
complex monitoring or those associated with acute and
hypersensitivity reactions, such as taxanes, bleomycin,
ifosfamide, cyclophosphamide, methotrexate, irinotecan,
oxaliplatin and etoposide, are not recommended for
home administration in France.
Regardless of country-specific recommendations, it
appears that home administration of chemotherapy is
not right for all patients and care givers, or for all types
of chemotherapy [26,30]. In addition, ensuring that care
is safe and effective is essential when considering the
place of home chemotherapy within any cancer service
[26,27,30].
We selected pemetrexed for this study because it has
several features that make it suitable for home-based ad-
ministration as maintenance therapy in patients with ad-
vanced NSCLC. In both registration studies, pemetrexed
maintenance therapy was well tolerated and reported
AEs were consistent with the known safety profile of the
drug [31]. Notably, there was no significant difference in
drug-related grade 3 or 4 toxic effects in patients receiv-
ing >6 cycles of therapy and patients receiving ≤6 cycles
of pemetrexed [17,18], although neutropenia was numer-
ically more common in one study (incidence of 9% in
patients receiving >6 cycles versus 4% in patients receiv-
ing ≤6 cycles; p = 0.062) [18]. Additionally, these studies
found that pemetrexed maintenance therapy had no over-
all detrimental effect on patients’ quality of life [32,33].
The efficacy of pemetrexed in NSCLC, together with its
favourable and well-characterised safety profile [31] and
ease of administration (as a 10-minute i.v. infusion) make
this drug an appropriate and suitable candidate for admin-
istration in an outpatient, home-based setting.
We identified a number of studies that evaluated the
feasibility, safety and clinical efficacy of home cytotoxic
chemotherapy, several in comparison with chemothe-rapy delivered in the hospital or outpatient setting
[9,11-13,34-45]. However, the results of these studies must
be considered in light of the fact that only three were
randomised controlled trials [11-13], one of which had
high withdrawal rates [12], and many studies were small
and provided limited data. In these studies, adult patients
with (most commonly) advanced colorectal, breast, head
and neck, or gynaecological cancer or bone metastases re-
ceived short i.v. infusions or bolus injections of cytotoxic
chemotherapy. A systematic review of these studies
showed that home administration of cytotoxic chemother-
apy was associated with similar rates of AEs (overall and
severe) as were found in the hospital setting, and that per-
manent withdrawal of patients from home administration
because of AEs or device-related complications occurred
infrequently [10]. Although none of the trials was powered
to detect differences in efficacy, no evidence was found to
suggest that there would be a difference in efficacy of
chemotherapy according to treatment administration loca-
tion. With respect to the acceptability of home-based
administration of cytotoxic chemotherapy, patients were
at least as satisfied with this location of treatment as they
were with outpatient or hospital-administered chemother-
apy [10], and evidence from randomised controlled trials
[12,13] suggests that HRQoL following cytotoxic chemo-
therapy was similar in both the home and hospital setting,
and that patients may prefer home administration [11,12].
Factors contributing to patient satisfaction with home-
based treatment included personalised care from nursing
staff, reduced difficulties with transport to hospital, fewer
financial concerns, less anxiety, and less disruption to daily
and family life.
We identified only one study of direct relevance to the
home-based administration of i.v. cytotoxic chemotherapy
in patients with NSCLC. That study evaluated the feasibil-
ity of home-based administration of i.v. gemcitabine
monotherapy for up to 6 months in chemo-naive patients
with advanced NSCLC and a PS of 0–2 [9]. In common
with our study design, patients received the first cycle
of chemotherapy in hospital and subsequent cycles at
home. The primary endpoint was the feasibility of home
administration, defined as a <25% reversion to hospital
care. Investigators found home-based administration of
chemotherapy to be feasible and acceptable to patients,
with only 1 of 24 patients requiring gemcitabine to be
changed from home to hospital administration [9]. Of 13
patients interviewed at the end of Cycle 2 of therapy, all
expressed a preference for home-based therapy for rea-
sons that included lower levels of stress, no travel, less
waiting around for treatment and more time at home to
carry out usual activities. Of the 13 informal carers
interviewed, 12 preferred home-based therapy.
The practicality of home administration of cytotoxic
agents is an important issue that we address in our study
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the provision of an efficient and effective home-based
chemotherapy care service. One is the challenge of pro-
viding treatment to patients at varying distances from
the hospital, particularly in Sweden – this study aims to
determine the feasibility both for patients in urban set-
tings and those who live many miles from hospital. One
way that we plan to alleviate some of the travelling re-
quired by home care nurses will involve the use of a spe-
cialist courier to deliver the drug to patients who live a
distance away from the site. In the study by Anderson
et al. [9], the distance travelled by home-based nurses
when visiting a patient ranged from 33 to 113 miles
(mean 51 miles). Although these distances did not in-
clude travel to the hospital to pick up the chemotherapy,
the authors concluded that transferring the administra-
tion of single-agent gemcitabine from the hospital to the
patients’ homes was a feasible option that did not appear
to increase the burden on community services and
warranted further investigation [9].
Another challenge to be overcome is the reconstitu-
tion of the drug prior to use on the day of infusion.
In our study, this is to be carried out by the site
pharmacy prior to being picked up by the home care
nurse or specialist courier and transported under re-
frigerated conditions within 24 hours of reconstitu-
tion, taking into account the stability properties of
pemetrexed.
Because patients will not be seen by their physician
before each cycle of maintenance chemotherapy, the
quality of nursing staff will be paramount when ad-
ministering the study drug, collecting laboratory re-
quired samples and conducting patient assessments as
per the protocol. Home care nurses in this study are
fully qualified, trained and experienced nurses and are
responsible for recognising, reporting and managing
(in the first instance) any serious AEs. Any future
home-based care programme of this nature will re-
quire the availability of similarly trained personnel to
assure the safety of the patient. Patients’ and investi-
gators’ satisfaction with the quality of the home nurse
staff, home care service and the distant management
of patients is also to be assessed during the study.
Due to the general lack of well-accepted standard
questionnaires in this setting, satisfaction with home
treatment and resource utilisation will be assessed
using a set of study-specific questions, developed
based on data from literature reviews and elaborated
by the study team. The assessment of resource use
outcomes is particularly relevant in patients with ad-
vanced NSCLC, as the management of this patient
group requires a multidisciplinary approach, involving
a range of medical specialities, including those man-
aging smoking and age-related co-morbidities.Conclusion
In oncology, home-based care is generally reserved for
the late palliative setting. This has led to a lack of inves-
tigations and data addressing home-based delivery of
cytotoxic chemotherapy. Regulations regarding home
delivery of cytotoxics differ across Europe, with a not-
able lack of practice guidelines in most countries, except
in France. The feasibility study discussed here will ad-
dress an important aspect of maintenance therapy in
NSCLC – patient comfort during protracted home-
based cytotoxic chemotherapy. The study design re-
quires unusual methodology and specific logistics to
address outcomes relevant to the home-delivery ap-
proach related to home delivery feasibility. Thus, pend-
ing the study results, this article presents a study design
that offers a novel and reproducible model for home-
based chemotherapy, and discusses the practicalities of
such an approach.
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